Abstract

Background

The aim of this prospective clinical quality assessment was to evaluate the short-term and long-term efficacy of low dose radiotherapy (RT) for calcaneodynia, achillodynia, painful gonarthrosis, painful bursitis trochanterica, and painful shoulder syndrome.

Methods

Between October 2011 and October 2013, patients with calcaneodynia, achillodynia, painful gonarthrosis, painful bursitis trochanterica, and painful shoulder syndrome were recruited for this prospective clinical quality assessment. Single doses of 0.5-1.0 Gy and a total dose of 6.0 Gy per series were used. Pain was measured before and directly after RT (early response) with a visual analogue scale (VAS). Additionally, pain relief was measured with the four-scale pain score according to “von Pannewitz” (VPS) immediately at the end of RT and during follow-up. Within this context we defined a good response as complete pain relief and markedly improved. The assessment of the long-term efficacy was carried out by a telephone survey.

Results

703 evaluable patients (461 female, 242 male) with a mean age of 63.2 years (28-96) were recruited for this prospective clinical quality assessment. In 254 patients RT was performed with the linear accelerator, 449 patients received orthovoltage radiotherapy. After a median follow-up of 33 months (3-60) 437 patients could be reached for evaluation of follow up results. The mean VAS value before treatment was 6.63 (1.9-10) and immediately on completion of RT 4.51 (0-10) (p < 0,001). Concerning the VPS immediately on completion of RT, a good response could be achieved in 264/703 patients (37.6%), and with the follow up in 255/437 patients (58.4%) (p < 0.001). Only in patients with gonarthrosis we could not observe a significantly improved long-term success in comparison to the results immediately after RT (30.2% versus 29.9%).

Conclusion

Low dose RT is a very effective treatment for the management of calcaneodynia, achillodynia, painful gonarthrosis, painful bursitis trochanterica, and painful shoulder syndrome. Due to the delayed onset of analgesic effects low dose RT results in a significantly improved long-term efficacy in comparison to the results immediately after RT particularly in patients with calcaneodynia, achillodynia, bursitis trochanterica, and shoulder syndrome.

Background

There is a long tradition for low dose radiotherapy (RT) of painful benign skeletal diseases in Central Europe. RT of benign diseases accounts for about 8–10% of all RT procedures in Germany. This development of radiotherapy for benign disorders in the last years can be reasonably regarded as real renaissance.

As much as 70% of these indications represent painful disorders in the locomotor system [1,2,3,4,5].

Recent radiobiological experiments show that low doses of radiation have a modulatory activity on several inflammatory pathways and immune components like endothelial cells, mono- and polynuclear leukocytes and macrophages [6].

For this treatment, single doses of 0.5 to 1.0 Gy and total doses of 3.0 to 6.0 Gy per series are generally accepted.

The aim of this prospective clinical quality assessment was to analyse the therapeutic effect of low dose irradiation immediately after completion of RT and during follow-up and to identify possible prognostic factors in patients with calcaneodynia, achillodynia, painful gonarthrosis, painful shoulder syndrome and painful bursitis trochanterica. It is a well-known observation, that the pain relief after RT often occurs after a longer period of time, generally 6 to 12 weeks [1,2,3]. However, this phenomenon is not well described and possible implication are not known. Therefore, we examined with this prospective clinical quality assessment, whether a delayed onset of analgesic effects of RT leads to a significantly improved long-term success in comparison to the results immediately after RT.

Methods

Between October 2011 and October 2013, patients with calcaneodynia, achillodynia, painful gonarthrosis, painful bursitis trochanterica, and painful shoulder syndrome were recruited for this prospective quality assessment. All patients had given their informed consent to the radiotherapy and to the participation in this prospective clinical quality assessment before enrolment.

RT was performed with both linear accelerator and orthovoltage conditions. Single doses of 0.5-1.0 Gy and a total dose of 6.0 Gy per series were used.

Pain was measured before and right after RT (early response) with a 10 scale visual analogue scale (VAS) (0 - no pain, 10 - strongest pain) [7]. Additionally, pain relief was measured with the four-scale pain score according to “von Pannewitz” (VPS) (complete pain relief, markedly improved, slightly improved, unchanged) immediately on completion of RT and during follow-up [8]. Within this context, we defined a good response as complete pain relief and markedly improved. The assessment of the long-term efficacy was carried out by a systematic telephone survey. The results were recorded in an Excel spreadsheet and then transferred to SPSS for evaluation after completion of the survey. A part of all treated patients were irradiated with a second series (n = 51), if there was no or only slight improvement after the first RT series. These results have been included in the evaluation.

Statistics

All data were stored and analyzed using the SPSS statistical package 15.0 (SPSS Inc., Chicago, Illinois, USA). Descriptive statistics were computed for continuous and categorical variables. The statistics computed included mean and standard deviations of continuous variables, and frequencies and relative frequencies of categorical factors. Testing for differences in continuous and categorical variables within the groups was accomplished by the Wilcoxon Signed Rank Test. Testing for differences in continuous variables between the groups was accomplished by the Mann-Whitney U test, and in categorical variables between the groups with the Fisher’s Exact Test, as appropriate. All P values were two-sided statistical tests, and values of P < .05 were considered statistically significant.

Treatment

In 254 patients RT was performed with the linear accelerator, 449 patients received orthovoltage radiotherapy. In 596 patients, RT was performed with 12 × 0.5 Gy, in 107 patients with 6 × 1.0 Gy. In 652 patients, RT was performed with one series, in 51 patients with two series in case of insufficient remission of pain after 3 months.

Vas

The median VAS value before treatment was 7.0 (5-8) and immediately on completion of RT 4.5 (3-6) (p < 0,001). Results for the different diagnoses are given in Table 2.

VPS immediately on completion of RT

A total of 29 patients (4.1%) were free of pain, 234 (33.3%) were much improved, 233 (33.1%) reported slight improvement, and 207 (29.5%) experienced no change.

VPS follow up

After a median follow-up of 33 months (3-60 months) 437 patients could be reached for evaluation of follow up results. 155 patients (35.5%) were free of pain, 100 (22.9%) had marked improvement, 65 (14.8%) had some improvement, and 117 (26.8%) experienced no change.

Comparison of VPS

A good response immediately on completion of RT could be achieved in 264/703 patients (37.6%), and with the follow up in 255/437 patients (58.4%) (p < 0.001). Only in patients with gonarthrosis we could not observe an increase of good response (30.2% immediately on completion of RT versus 29.9% at the follow up time).

Further results

Results regarding fractionation, number of series, and radiation unit (only for gonarthrosis, bursitis trochanterica, and shoulder syndrome) are given in Tables 5 and 6. Further significant differences between the groups were not found. No side effects have been observed.

Table 5 Influence of number of series, single dose, and gender on Good Reponse on completion of RT, and Good Reponse - Follow up

The precise pathophysiological mechanisms of pain relief after RT are still not well defined. Recent radiobiological experiments show that low doses of radiation have an anti-inflammatory efficacy based on the modulation of a multitude of inflammatory pathways and cellular components. This includes immune components like endothelial cells, mono- and polynuclear leukocytes and macrophages, and an influence on the vascular endothelium with improved tissue perfusion, destruction of inflammatory cells (in particular lymphocytes) with release of cytokines and proteolytic enzymes, modulation of the vegetative nervous system, altering of the tissue pH and increased membrane permeability. Most likely, irradiation does not act through a single mechanism but through a complex interaction of different effects [6].

We observed a significantly improved long-term efficacy in comparison to the results immediately after RT in patients with calcaneodynia, achillodynia, bursitis trochanterica, and shoulder syndrome. This could be due to the delayed clinical onset of effects, which is most likely due to the also delayed onset of above mentioned radiobiological mechanisms. However, the group of patients with gonarthrosis was the only one without this observed delayed effect. Most likely, with low dose RT we can achieve more complete remissions in patients with calcaneodynia, achillodynia, bursitis trochanterica, and shoulder syndrome. In contrast, gonarthrosis is described to be an irreversible pathological process, with cartilaginous and bony destructions, which cannot reversed by radiotherapy. These irreversible destructions initiate a variety inflammatory processes leading to pain, swelling etc. under the clinical picture of activated osteoarthritis [8, 9]. Here, low doses RT may be helpful by alleviation of inflammation and pain in these acute episodes of this chronic joint disorders. However, the underlying pathophysiological problem remains more or less unchanged by RT, even so RT can arrest and slow down the progressive joint destruction in osteoarthritis by the anti-inflammatory effect of low dose RT. Therefore, the analgesic effect is only moderate compared to other indications, in particular the enthesiopathies [1, 4, 8].

Clearly, a possible placebo effect of low dose RT for pain treatment cannot completely be excluded. In previously published early double-blinded studies from the 1970s, a large variety of different degenerative skeletal diseases were treated with low-dose RT. These studies could not prove a significantly higher response for the RT group in comparison to the placebo group [24,25,26].

Radiation side effects did not occur in any of our patients. This corresponds to the reported absence of chronic or acute adverse effects in the literature [9,10,11,12,13,14,15,16,17,18,19,20,21,22,23].

Conclusion

Low dose RT is a very effective treatment for the management of calcaneodynia, achillodynia, painful gonarthrosis, painful bursitis trochanterica, and painful shoulder syndrome. Due to the delayed onset of analgesic effects low dose RT results in a significantly improved long-term efficacy in comparison to the results immediately after RT particularly in patients with calcaneodynia, achillodynia, bursitis trochanterica, and shoulder syndrome.

Abbreviations

Gy:

Gray

RT:

Radiotherapy

VAS:

Visual analogue scale

VPS:

von Pannewitz Score

References

1.

Seegenschmiedt MH, Micke O, Muecke R, German Cooperative Group on Radiotherapy for Non-malignant Diseases (GCG-BD). Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines. Br J Radiol. 2015;88:20150080.

Contributions

OM and RM were the principle investigators of the prospective clinical quality assessment. OM, EU, SB, IAA, US, RB, KK, MHS, KF and RM participated in the design of the prospective clinical quality assessment, its coordination, and performed a part of the statistical analysis. RM, EU, SB, US, RB and KF participated in the patient accrual and the follow-up examinations. OM, RM, IAA, US, KK and MHS drafted the manuscript. All authors read and approved the final manuscript.

Corresponding author

Ethics declarations

Ethics approval and consent to participate

This prospective quality assessment study contains only established treatment concepts. Therefore, an ethical approval was not needed. Nevertheless, a written informed consent was obtained from every patient.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Keywords

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.